Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts

Annals of Hematology, Supplement

Volumn 84, Issue 13, 2005, Pages 54-60

  Gozzini, Antonella ^a   Santini, Valeria ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

HDACi; Histone acetylation; Hypomethylation

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA METHYLTRANSFERASE; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; O N BUTANOIL 2,3 O ISOPROPYLIDENE ALPHA MANNOFURANOSIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; AZACITIDINE; BUTYRIC ACID DERIVATIVE; DRUG DERIVATIVE; MANNOSE; O N BUTANOYL 2,3 O ISOPROPYLIDENEMANNOFURANOSIDE; O-N-BUTANOYL-2,3-O-ISOPROPYLIDENEMANNOFURANOSIDE; DNA; DNA METHYLTRANSFERASE INHIBITOR; HISTONE ACETYLTRANSFERASE; HISTONE METHYLTRANSFERASE; LYSINE; O N BUTANOIL 2,3 O ISOPROPYLIDENE ALPHA DEXTRO MANNOFURANOSIDE; TRANSCRIPTION FACTOR; NUCLEAR RECEPTOR COREPRESSOR; ONCOPROTEIN;

ACETYLATION; ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLAST CELL; CANCER INHIBITION; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; CELL DIFFERENTIATION; CELL TRANSFORMATION; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; GENE SILENCING; GENE TRANSLOCATION; GENETIC EPIGENESIS; GENETICS; GRANULOCYTE; TUMOR CELL LINE; CELL CYCLE REGULATION; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 8; COMBINATION CHEMOTHERAPY; COMPLEX FORMATION; CPG ISLAND; DNA METHYLATION; DNA PROTEIN COMPLEX; ENZYME ACTIVITY; EPIGENETICS; EUCHROMATIN; EUKARYOTIC CELL; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE REPRESSION; GENETIC TRANSCRIPTION; HETEROCHROMATIN; LEUKEMIA CELL; LEUKEMOGENESIS; METHYLATION; MITOSIS INHIBITION; MONOTHERAPY; NUCLEOSOME; PROMOTER REGION; TRANSCRIPTION REGULATION; DEACETYLATION; GENE EXPRESSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; BUTYRATES; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DNA MODIFICATION METHYLASES; EPIGENESIS, GENETIC; GENE SILENCING; GRANULOCYTES; HISTONE DEACETYLASES; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MANNOSE; TRANSLOCATION, GENETIC;

EID: 29144501152     PISSN: 09458077     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-005-0006-z     Document Type: Article

References (38)

1. Alcalay M, Orleth A, Sebastiani C, Meani N, Chiaradonna F, Casciari C, Sciupi MT, Gelmetti V, Riganelli D, Minacci S, Fagioli M, Pelicci PG (2001) Common themes in the pathogenesis of acute myeloid leukemia. Oncogene 10:5680-5694 10.1038/sj.onc.1204642
2. Asou H, Tashiro S, Hamamoto K, Osuji A, Kita K, Kamada N (1991) Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood 77:2031-2036 2018839
3. Bergmann L, Maurer U, Weidmann E (1997) Wilm's tumor gene expression in acute myeloid leukemias. Leuk Lymphoma 25:435-443 9250813
4. Cheung P, Lau P (2005) Epigenetic regulation by histone methylation and histone variants. Mol Endocrinol 19:563-573 10.1210/me.2004-0496
5. Cilloni D, Saglio G (2004) WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome. Acta Haematol 112:79-84 10.1159/000077562
6. Davie JR (1997) Nuclear matrix, dynamic histone acetylation and transcriptionally active chromatin. Mol Biol Rep 24:197-207 10.1023/ A:1006811817247
7. Di Croce L, Raker VA, Corsaro M, Fazi F, Fanelli M, Faretta M, Fuks F, Lo Coco F, Kouzarides T, Nervi C, Minucci S, Pelicci PG (2002) Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295:1079-1082
8. Downing JR (1999) The AML1-ETO chimaeric transcription factor in acute myeloid leukaemia: Biology and clinical significance. Br J Haematol 106:296-308 10.1046/j.1365-2141.1999.01377.x
9. Drummond CD, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC (2005) Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 45:495-528 10.1146/ annurev.pharmtox.45.120403.095825
10. Eden S, Hashimshony T, Keshet I, Cedar H, Thorne AW (1998) DNA methylation models histone acetylation. Nature 394:842 10.1038/29680
11. Fazi F, Travaglini L, Carotti D, Palitti F, Diverio D, Alcalay M, McNamara S, Miller WH, Coco FL, Pelicci PG, Nervi C (2005) Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo. Oncogene 24:1820-1830 10.1038/ sj.onc.1208286
12. Felsenfeld G, Groudine M (2003) Controlling the double helix. Nature 42:448-453 10.1038/nature01411
13. Fliegauf M, Stock M, Berg T, Lubbert M (2004) Williams-Beuren syndrome critical region-5/non-T-cell activation linker: A novel target gene of AML1/ETO. Oncogene 23:9070-9081 10.1038/sj.onc.1208042
14. Gelmetti V, Zhang J, Fanelli M, Minacci S, Pelicci PG, Lazar MA (1998) Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol 18:7185-7191 9819405
15. Gilbert J, Gore SD, Herman JG, Carducci MA (2004) The clinical application of targeting cancer through histone acetylation and hypomethylation. Clin Cancer Res 10:4589-4596 10.1158/ 1078-0432.CCR-03-0297
16. Gore SD, Weng LJ, Zhai S, Figg WD, Donehower RC, Dover GJ, Grever M, Griffin CA, Grochow LB, Rowinsky EK, Zabalena Y, Hawkins AL, Burks K, Miller CB (2001) Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res 7:2330-2339 11489809
17. Gozzini A, Rovida E, Dello Sbarba P, Galimberti S, Santini V (2003) Butyrates, as a single drug, induce histone acetylation and granulocytic maturation: Possible selectivity on core binding factor-acute myeloid leukemia blasts. Cancer Res 24:8955-8961
18. Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042-2054 10.1056/ NEJMra023075
19. Jones PA, Taylor SM (1990) Cellular differentiation, cytidine analogs and DNA methylation. Cell 20:85-93 10.1016/0092-8674(80)90237-8
20. Klisovic MI, Maghraby EA, Parthun MR, Guimond M, Sklenar AR, Whitman SP, Chan KK, Murphy T, Anon J, Archer KJ, Rush LJ, Plass C, Grever MR, Byrd JC, Marcucci G (2003) Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. Leukemia 17:350-358 10.1038/sj.leu.2402776
21. Kuendgen A, Strupp C, Aivado M, Bernhardt A, Hildebrandt B, Haas R, Germing U, Gattermann N (2004) Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 104:1266-1269 10.1182/blood-2003-12-4333
22. Leone G, Voso MT, Teofili L, Lubbert M (2003) Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. Clin Immunol 109:89-102 10.1016/S1521-6616(03)00207-9
23. Liu S, Shen T, Huynh L, Klisovic MI, Rush LJ, Ford JL, Yu J, Becknell B, Li Y, Liu C, Vukosavljevic T, Whitman SP, Chang KS, Byrd JC, Perrotti D, Plass C, Marcucci G (2005) Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. Cancer Res 65:1277-1284 10.1158/0008-5472.CAN-04-4532
24. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402-408 10.1006/meth.2001.1262
25. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK (2001) Histone deacetylases and cancer: Causes and therapies. Nature Rev Cancer 1:194-202 10.1038/35106079
26. Minucci S, Nervi C, Lo Coco F, Pelicci PG (2001) Histone deacetylases: A common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene 20:3110-3115 10.1038/sj.onc.1204336
27. Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y (1996) The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87:953-959 8945521
28. Partha M, Singal R (2004) DNA methylation and cancer. J Clin Oncol 22: 4632-4642 10.1200/JCO.2004.07.151
29. Piekarz R, Bates S (2004) A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm Des 10:2289-2298 10.2174/1381612043383980
30. Pouillart P, Douillet O, Scappini B, Gozzini A, Santini V, Grossi A, Pagliai G, Strippoli P, Rigacci L, Ronco G, Villa P (1999) Regioselective synthesis and biological profiling of butyric and phenylalkylcarboxylic esters derivated from d-mannose and xylitol: influence of alkyl chain length on acute toxicity. Eur J Pharm Sci 7:93-106
31. Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA, Marks PA (1998) A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A 95:3003-3007 10.1073/pnas.95.6.3003
32. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T, Nakanishi O (1999) A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci U S A 96:4592-4597 10.1073/ pnas.96.8.4592
33. Santini V, Scappini B, Gozzini A, Grossi A, Villa P, Ronco G, Douillet O, Pouillart P, Bernabei PA, Rossi Ferrini P (1998) Butyrate-stable monosaccharide derivatives induce maturation and apoptosis in human acute myeloid leukaemia cell. Br J Haematol 101:529-538 10.1046/ j.1365-2141.1998.00727.x
34. Santini V, Kantarjian HM, Issa JP (2001) Changes in DNA methylation in neoplasia: Pathophysiology and therapeutic implications. Ann Intern Med 134:573-86 11281740
35. Schmelz K, Sattler N, Wagner M, Lubbert M, Dorken B, Tamm I (2005) Induction of gene expression by 5-aza-2′-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms. Leukemia 19:103-111 15510208
36. Shaker S, Bernstein M, Momparler LF, Momparler RL (2003) Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2′-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells. Leuk Res 27:437-444 10.1016/S0145-2126(02)00222-9
37. Wade PA, Jones PL, Vermaak D, Veenstra GJC, Imhof A, Sera T, Tse C, Ge H, Shi Y-B, Hansen JC, Wolffe AP (1998) Histone deacetylase directs the dominant silencing of transcription in chromatin: Association with MeCP2 and the Mi-2 chromodomain SWI/SNF ATPase. Cold Spring Harbor Symposia on Quantitative Biology, Symposium 63:435-446
38. Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM (1998) Protein ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1complex. Proc Natl Acad Sci U S A 95:10860-10865 10.1073/pnas.95.18.10860